Importer of Controlled Substances; Notice of Application, 27347-27349 [E9-13357]
Download as PDF
<![CDATA[
27347
Federal Register / Vol. 74, No. 109 / Tuesday, June 9, 2009 / Notices
FOR FURTHER INFORMATION CONTACT:
Patrick W. McDonough, Executive
Director of the Joint Board for the
Enrollment of Actuaries, 202–622–8225.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Advisory
Committee on Actuarial Examinations
will meet in the Internal Revenue
Service Building, 1111 Constitution
Avenue, NW., Washington, DC on
Monday, June 29, 2009, from 9 a.m. to
5 p.m., and Tuesday, June 30, 2009,
from 8:30 a.m. to 5 p.m.
The purpose of the meeting is to
discuss topics and questions which may
be recommended for inclusion on future
Joint Board examinations in actuarial
mathematics and methodology referred
to in 29 U.S.C. 1242(a)(1)(B) and to
review the May 2009 Basic (EA–1) and
Pension (EA–2B) Joint Board
Examinations in order to make
recommendations relative thereto,
including the minimum acceptable pass
score. Topics for inclusion on the
syllabus for the Joint Board’s
examination program for the November
2009 Pension (EA–2A) Examination will
be discussed.
A determination has been made as
required by section 10(d) of the Federal
Advisory Committee Act, 5 U.S.C. App.,
that the portions of the meeting dealing
with the discussion of questions that
may appear on the Joint Board’s
examinations and the review of the May
2009 Joint Board examinations fall
within the exceptions to the open
meeting requirement set forth in 5
U.S.C. 552b(c)(9)(B), and that the public
interest requires that such portions be
closed to public participation.
The portion of the meeting dealing
with the discussion of the other topics
will commence at 1 p.m. on June 29 and
will continue for as long as necessary to
complete the discussion, but not beyond
3 p.m. Time permitting, after the close
of this discussion by Committee
members, interested persons may make
statements germane to this subject.
Persons wishing to make oral statements
must notify the Executive Director in
writing prior to the meeting in order to
aid in scheduling the time available and
must submit the written text, or at a
minimum, an outline of comments they
propose to make orally. Such comments
will be limited to 10 minutes in length.
All other persons planning to attend the
public session must also notify the
Executive Director in writing to obtain
building entry. Notifications of intent to
make an oral statement or to attend
must be faxed, no later than June 19,
2009, to 202–622–8300, Attn: Executive
Director. Any interested person also
may file a written statement for
VerDate Nov<24>2008
16:42 Jun 08, 2009
Jkt 217001
consideration by the Joint Board and the
Committee by sending it to the
Executive Director: Joint Board for the
Enrollment of Actuaries, c/o Internal
Revenue Service, Attn: Executive
Director SE:OPR, Room 7238, 1111
Constitution Avenue, NW., Washington,
DC 20224.
Dated: May 26, 2009.
Patrick W. McDonough,
Executive Director, Joint Board for the
Enrollment of Actuaries.
[FR Doc. E9–13517 Filed 6–8–09; 8:45 am]
BILLING CODE 4830–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
This is notice that on January 28,
2009, Stepan Company, Natural
Products Department, 100 W. Hunter
Avenue, Maywood, New Jersey 07607,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
Coca Leaves (9040), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for the
manufacture of a bulk controlled
substance for distribution to its
customer.
No comments, objections, or requests
for any hearings will be accepted on any
application for registration or reregistration to import coca leaves. As
explained in the Correction to Notice of
Application pertaining to Rhodes
Technologies, 72 FR 3417 (2007),
comments and requests for hearings on
applications to import narcotic raw
material are not appropriate.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Springfield, VA 22152; and must be
filed no later than July 9, 2009.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13353 Filed 6–8–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on March
18, 2009, Research Triangle Institute,
Kenneth H. Davis Jr., Hermann
Building, East Institute Drive, P.O. Box
12194, Research Triangle, North
Carolina 27709, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-[1-(2-Thienyl)cyclohexy]piperidine (7470).
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473).
E:\FR\FM\09JNN1.SGM
09JNN1
Schedule
I
I
I
27348
Federal Register / Vol. 74, No. 109 / Tuesday, June 9, 2009 / Notices
Drug
Schedule
1-Methyl-4-phenyl-4propionoxypiperidine (9661).
1-(2-Phenylethyl)-4-phenyl-4acetoxypiperidine (9663).
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
2,5-Dimethoxy-4ethylamphetamine (7399).
2,5-Dimethoxyamphetamine
(7396).
3,4,5-Trimethoxyamphetamine
(7390).
3,4-Methylenedioxyamphetamine
(7400).
3,4Methylenedioxymethamphetamine (7405).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3-Methylfentanyl (9813) ................
3-Methylthiofentanyl (9833) ..........
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
4-Methylaminorex (cis isomer)
(1590).
4-Methoxyamphetamine (7411) ...
5-Methoxy-3,4methylenedioxyamphetamine
(7401).
5-Methoxy-N,Ndiisopropyltryptamine (7439).
Acetorphine (9319) .......................
Acetyl-alpha-methylfentanyl
(9815).
Acetyldihydrocodeine (9051) ........
Acetylmethadol (9601) .................
Allylprodine (9602) .......................
Alphacetylmethadol except levoalphacetylmethadol (9603).
Alpha-ethyltryptamine (7249) .......
Alphameprodine (9604) ................
Alphamethadol (9605) ..................
Alpha-methylfentanyl (9814) ........
Alpha-methylthiofentanyl (9832) ...
Alpha-methyltryptamine (7432) ....
Aminorex (1585) ...........................
Benzethidine (9606) .....................
Benzylmorphine (9052) ................
Betacetylmethadol (9607) ............
Beta-hydroxy-3-methylfentanyl
(9831).
Beta-hydroxyfentanyl (9830) ........
Betameprodine (9608) ..................
Betamethadol (9609) ....................
Betaprodine (9611) .......................
Bufotenine (7433) .........................
Cathinone (1235) ..........................
Clonitazene (9612) .......................
Codeine methylbromide (9070) ....
Codeine-N-Oxide (9053) ..............
Cyprenorphine (9054) ..................
Desomorphine (9055) ...................
Dextromoramide (9613) ...............
Diampromide (9615) .....................
Diethylthiambutene (9616) ...........
Diethyltryptamine (7434) ..............
Difenoxin (9168) ...........................
Dihydromorphine (9145) ...............
VerDate Nov<24>2008
14:45 Jun 08, 2009
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Jkt 217001
Drug
Schedule
Dimenoxadol (9617) .....................
Dimepheptanol (9618) ..................
Dimethylthiambutene (9619) ........
Dimethyltryptamine (7435) ...........
Dioxaphetyl butyrate (9621) .........
Dipipanone (9622) ........................
Drotebanol (9335) ........................
Ethylmethylthiambutene (9623) ....
Etonitazene (9624) .......................
Etorphine except HCl (9056) ........
Etoxeridine (9625) ........................
Fenethylline (1503) .......................
Furethidine (9626) ........................
Gamma
Hydroxybutyric
Acid
(2010).
Heroin (9200) ...............................
Hydromorphinol (9301) .................
Hydroxypethidine (9627) ..............
Ibogaine (7260) ............................
Ketobemidone (9628) ...................
Levomoramide (9629) ..................
Levophenacylmorphan (9631) ......
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Mecloqualone (2572) ....................
Mescaline (7381) ..........................
Methaqualone (2565) ...................
Methcathinone (1237) ..................
Methyldesorphine (9302) ..............
Methyldihydromorphine (9304) .....
Morpheridine (9632) .....................
Morphine methylbromide (9305) ..
Morphine methylsulfonate (9306)
Morphine-N-Oxide (9307) .............
Myrophine (9308) .........................
N,N-Dimethylamphetamine (1480)
N-[1-(2-thienyl)methyl-4-piperidyl]N-phenylpropanamide (9834).
N-[1-benzyl-4-piperidyl]-Nphenylpropanamide (9818).
N-Benzylpiperazine (7493) ...........
N-Ethyl-3-piperidyl
benzilate
(7482).
N-Ethylamphetamine (1475) ........
N-Ethyl-l-phenylcyclohexylamine
(7455).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
Nicocodeine (9309) ......................
Nicomorphine (9312) ....................
N-Methyl-3-piperidyl
benzilate
(7484).
Noracymethadol (9633) ................
Norlevorphanol (9634) ..................
Normethadone (9635) ..................
Normorphine (9313) .....................
Norpipanone (9636) .....................
Para-Fluorofentanyl (9812) ..........
Parahexyl (7374) ..........................
Peyote (7415) ...............................
Phenadoxone (9637) ....................
Phenampromide (9638) ................
Phenomorphan (9647) .................
Phenoperidine (9641) ...................
Pholcodine (9314) ........................
Piritramide (9642) .........................
Proheptazine (9643) .....................
Properidine (9644) ........................
Propiram (9649) ...........................
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Racemoramide (9645) ..................
Tetrahydrocannabinols (7370) .....
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Drug
Thebacon (9315) ..........................
Thiofentanyl (9835) ......................
Tilidine (9750) ...............................
Trimeperidine (9646) ....................
Thiofentanyl (9835) ......................
1-Phenylcyclohexylamine (7460)
1Piperidinocyclohexanecarbonitrile (8603).
Alfentanil (9737) ...........................
Alphaprodine (9010) .....................
Amobarbital (2125) .......................
Amphetamine (1100) ....................
Anileridine (9020) .........................
Bezitramide (9800) .......................
Carfentanil (9743) .........................
Coca Leaves (9040) .....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Dihydrocodeine (9120) .................
Dihydroetorphine (9334) ...............
Diphenoxylate (9170) ...................
Ethylmorphine (9190) ...................
Etorphine Hcl (9059) ....................
Fentanyl (9801) ............................
Glutethimide (2550) ......................
Hydrocodone (9193) .....................
Hydromorphone (9150) ................
Isomethadone (9226) ...................
Levo-alphacetylmethadol (9648) ..
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Lisdexamfetamine (1205) .............
Meperidine (9230) ........................
Meperidine intermediate-A (9232)
Meperidine intermediate-B (9233)
Meperidine intermediate-C (9234)
Metazocine (9240) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Metopon (9260) ............................
Moramide intermediate (9802) .....
Morphine (9300) ...........................
Nabilone (7379) ............................
Opium, raw (9600) .......................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, granulated (9640) ............
Oxycodone (9143) ........................
Oxymorphone (9652) ...................
Pentobarbital (2270) .....................
Phenazocine (9715) .....................
Phencyclidine (7471) ....................
Phenmetrazine (1631) ..................
Phenylacetone (8501) ..................
Piminodine (9730) ........................
Powdered opium (9639) ...............
Racemethorphan (9732) ..............
Racemorphan (9733) ...................
Remifentanil (9739) ......................
Secobarbital (2315) ......................
Sufentanil (9740) ..........................
Thebaine (9333) ...........................
Schedule
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import small
quantities of the listed controlled
substances for the National Institute on
Drug Abuse (NIDA) for research
activities.
E:\FR\FM\09JNN1.SGM
09JNN1
27349
Federal Register / Vol. 74, No. 109 / Tuesday, June 9, 2009 / Notices
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, Virginia 22152; and
must be filed no later than July 9, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13357 Filed 6–8–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2), authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
VerDate Nov<24>2008
14:45 Jun 08, 2009
Jkt 217001
Therefore, in accordance with Title
21, Code of Federal Regulations (CFR),
1301.34(a), this is notice that on January
5, 2009, Mylan Pharmaceuticals Inc.,
781 Chestnut Ridge Road, Morgantown,
West Virginia 26505, made application
by letter to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Methylphenidate (1724) ................
Fentanyl (9801) ............................
II
II
The company plans to import the
listed controlled substances for
analytical research and clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 9, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13360 Filed 6–8–09; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2), authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on January
5, 2009, Mylan Technologies Inc., 110
Lake Street, Saint Albans, Vermont
05478, made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
Methylphenidate (1724) ................
Fentanyl (9801) ............................
Schedule
II
II
The company plans to import the
listed controlled substances for
analytical research and clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 9, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
E:\FR\FM\09JNN1.SGM
09JNN1
]]>Agencies
[Federal Register Volume 74, Number 109 (Tuesday, June 9, 2009)]
[Notices]
[Pages 27347-27349]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-13357]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on March 18, 2009, Research
Triangle Institute, Kenneth H. Davis Jr., Hermann Building, East
Institute Drive, P.O. Box 12194, Research Triangle, North Carolina
27709, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of the basic
classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
1-(1-Phenylcyclohexyl)pyrrolidine (7458)... I
1-[1-(2-Thienyl)cyclohexy]piperidine (7470) I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine I
(7473).
[[Page 27348]]
1-Methyl-4-phenyl-4-propionoxypiperidine I
(9661).
1-(2-Phenylethyl)-4-phenyl-4- I
acetoxypiperidine (9663).
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
2,5-Dimethoxyamphetamine (7396)............ I
3,4,5-Trimethoxyamphetamine (7390)......... I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxymethamphetamine (7405)... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3-Methylfentanyl (9813).................... I
3-Methylthiofentanyl (9833)................ I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
4-Methylaminorex (cis isomer) (1590)....... I
4-Methoxyamphetamine (7411)................ I
5-Methoxy-3,4-methylenedioxyamphetamine I
(7401).
5-Methoxy-N,N-diisopropyltryptamine (7439). I
Acetorphine (9319)......................... I
Acetyl-alpha-methylfentanyl (9815)......... I
Acetyldihydrocodeine (9051)................ I
Acetylmethadol (9601)...................... I
Allylprodine (9602)........................ I
Alphacetylmethadol except levo- I
alphacetylmethadol (9603).
Alpha-ethyltryptamine (7249)............... I
Alphameprodine (9604)...................... I
Alphamethadol (9605)....................... I
Alpha-methylfentanyl (9814)................ I
Alpha-methylthiofentanyl (9832)............ I
Alpha-methyltryptamine (7432).............. I
Aminorex (1585)............................ I
Benzethidine (9606)........................ I
Benzylmorphine (9052)...................... I
Betacetylmethadol (9607)................... I
Beta-hydroxy-3-methylfentanyl (9831)....... I
Beta-hydroxyfentanyl (9830)................ I
Betameprodine (9608)....................... I
Betamethadol (9609)........................ I
Betaprodine (9611)......................... I
Bufotenine (7433).......................... I
Cathinone (1235)........................... I
Clonitazene (9612)......................... I
Codeine methylbromide (9070)............... I
Codeine-N-Oxide (9053)..................... I
Cyprenorphine (9054)....................... I
Desomorphine (9055)........................ I
Dextromoramide (9613)...................... I
Diampromide (9615)......................... I
Diethylthiambutene (9616).................. I
Diethyltryptamine (7434)................... I
Difenoxin (9168)........................... I
Dihydromorphine (9145)..................... I
Dimenoxadol (9617)......................... I
Dimepheptanol (9618)....................... I
Dimethylthiambutene (9619)................. I
Dimethyltryptamine (7435).................. I
Dioxaphetyl butyrate (9621)................ I
Dipipanone (9622).......................... I
Drotebanol (9335).......................... I
Ethylmethylthiambutene (9623).............. I
Etonitazene (9624)......................... I
Etorphine except HCl (9056)................ I
Etoxeridine (9625)......................... I
Fenethylline (1503)........................ I
Furethidine (9626)......................... I
Gamma Hydroxybutyric Acid (2010)........... I
Heroin (9200).............................. I
Hydromorphinol (9301)...................... I
Hydroxypethidine (9627).................... I
Ibogaine (7260)............................ I
Ketobemidone (9628)........................ I
Levomoramide (9629)........................ I
Levophenacylmorphan (9631)................. I
Lysergic acid diethylamide (7315).......... I
Marihuana (7360)........................... I
Mecloqualone (2572)........................ I
Mescaline (7381)........................... I
Methaqualone (2565)........................ I
Methcathinone (1237)....................... I
Methyldesorphine (9302).................... I
Methyldihydromorphine (9304)............... I
Morpheridine (9632)........................ I
Morphine methylbromide (9305).............. I
Morphine methylsulfonate (9306)............ I
Morphine-N-Oxide (9307).................... I
Myrophine (9308)........................... I
N,N-Dimethylamphetamine (1480)............. I
N-[1-(2-thienyl)methyl-4-piperidyl]-N- I
phenylpropanamide (9834).
N-[1-benzyl-4-piperidyl]-N- I
phenylpropanamide (9818).
N-Benzylpiperazine (7493).................. I
N-Ethyl-3-piperidyl benzilate (7482)....... I
N-Ethylamphetamine (1475).................. I
N-Ethyl-l-phenylcyclohexylamine (7455)..... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
Nicocodeine (9309)......................... I
Nicomorphine (9312)........................ I
N-Methyl-3-piperidyl benzilate (7484)...... I
Noracymethadol (9633)...................... I
Norlevorphanol (9634)...................... I
Normethadone (9635)........................ I
Normorphine (9313)......................... I
Norpipanone (9636)......................... I
Para-Fluorofentanyl (9812)................. I
Parahexyl (7374)........................... I
Peyote (7415).............................. I
Phenadoxone (9637)......................... I
Phenampromide (9638)....................... I
Phenomorphan (9647)........................ I
Phenoperidine (9641)....................... I
Pholcodine (9314).......................... I
Piritramide (9642)......................... I
Proheptazine (9643)........................ I
Properidine (9644)......................... I
Propiram (9649)............................ I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
Racemoramide (9645)........................ I
Tetrahydrocannabinols (7370)............... I
Thebacon (9315)............................ I
Thiofentanyl (9835)........................ I
Tilidine (9750)............................ I
Trimeperidine (9646)....................... I
Thiofentanyl (9835)........................ I
1-Phenylcyclohexylamine (7460)............. II
1-Piperidinocyclohexanecarbonitrile (8603). II
Alfentanil (9737).......................... II
Alphaprodine (9010)........................ II
Amobarbital (2125)......................... II
Amphetamine (1100)......................... II
Anileridine (9020)......................... II
Bezitramide (9800)......................... II
Carfentanil (9743)......................... II
Coca Leaves (9040)......................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Dihydrocodeine (9120)...................... II
Dihydroetorphine (9334).................... II
Diphenoxylate (9170)....................... II
Ethylmorphine (9190)....................... II
Etorphine Hcl (9059)....................... II
Fentanyl (9801)............................ II
Glutethimide (2550)........................ II
Hydrocodone (9193)......................... II
Hydromorphone (9150)....................... II
Isomethadone (9226)........................ II
Levo-alphacetylmethadol (9648)............. II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Lisdexamfetamine (1205).................... II
Meperidine (9230).......................... II
Meperidine intermediate-A (9232)........... II
Meperidine intermediate-B (9233)........... II
Meperidine intermediate-C (9234)........... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Metopon (9260)............................. II
Moramide intermediate (9802)............... II
Morphine (9300)............................ II
Nabilone (7379)............................ II
Opium, raw (9600).......................... II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, granulated (9640)................... II
Oxycodone (9143)........................... II
Oxymorphone (9652)......................... II
Pentobarbital (2270)....................... II
Phenazocine (9715)......................... II
Phencyclidine (7471)....................... II
Phenmetrazine (1631)....................... II
Phenylacetone (8501)....................... II
Piminodine (9730).......................... II
Powdered opium (9639)...................... II
Racemethorphan (9732)...................... II
Racemorphan (9733)......................... II
Remifentanil (9739)........................ II
Secobarbital (2315)........................ II
Sufentanil (9740).......................... II
Thebaine (9333)............................ II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances for the National Institute on Drug Abuse (NIDA)
for research activities.
[[Page 27349]]
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537, or any being sent via express mail should be sent
to Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be filed no later than July 9,
2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e) and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substances in schedule I or II are and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-13357 Filed 6-8-09; 8:45 am]
BILLING CODE 4410-09-P
